Mazdutide
$30.00
Mazdutide (IBI362 / LY3305677 / Dual GLP-1 & Glucagon Receptor Agonist Peptide)
Description:
Mazdutide is a next-generation dual receptor agonist peptide that targets both GLP-1 (glucagon-like peptide-1) and glucagon (GCG) receptors. Designed to mimic the natural gut hormone oxyntomodulin (OXM), it exhibits a balanced dual agonist effect that enhances insulin sensitivity, suppresses appetite, and increases energy expenditure. Mazdutide has been studied for its potential to support weight reduction, glucose regulation, and liver fat metabolism, making it a leading candidate in metabolic and obesity research.
Key Benefits:
Promotes significant body fat reduction and appetite control
Enhances glucose-dependent insulin secretion and glycemic balance
Increases energy expenditure and lipid metabolism
Reduces liver fat and improves lipid and blood pressure profiles
Supports studies in obesity, metabolic disorders, and hepatic steatosis
Mechanism of Action:
Mazdutide acts through dual receptor activation, targeting both GLP-1 and glucagon receptors:
GLP-1 receptor stimulation enhances insulin secretion, suppresses glucagon release, delays gastric emptying, and reduces appetite.
Glucagon receptor stimulation increases hepatic fat utilization and energy expenditure through mild thermogenic activity.
The combined action provides synergistic metabolic benefits, improving weight management, glucose stability, and lipid oxidation. This dual-pathway approach makes Mazdutide a promising research compound for obesity and type 2 diabetes models.
Molecular Type: Dual GLP-1R / GCGR peptide agonist
Synonyms: IBI362, LY3305677
Molecular Weight: Variable (modified peptide conjugate)
Form: Lyophilized powder for reconstitution or sterile solution
Purity: ≥98% (HPLC)
Storage:
Store at −20 °C. Protect from light, heat, and moisture. Once reconstituted, refrigerate (2–8 °C) and use within 30 days. Avoid repeated freeze–thaw cycles.
Disclaimer:
For laboratory research use only. Not for human consumption.